Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2025)

Amylyx Pharmaceuticals has reported Total Current Liabilities over the past 5 years, most recently at $22.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $22.7 million for Q4 2025, down 20.13% from a year ago — trailing twelve months through Dec 2025 was $22.7 million (down 20.13% YoY), and the annual figure for FY2025 was $22.7 million, down 20.13%.
  • Total Current Liabilities for Q4 2025 was $22.7 million at Amylyx Pharmaceuticals, down from $25.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for AMLX hit a ceiling of $91.6 million in Q1 2024 and a floor of $17.4 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $32.6 million (2022), compared with a mean of $42.8 million.
  • Biggest five-year swings in Total Current Liabilities: surged 167.93% in 2022 and later tumbled 80.43% in 2025.
  • Amylyx Pharmaceuticals' Total Current Liabilities stood at $17.4 million in 2021, then surged by 167.93% to $46.6 million in 2022, then soared by 76.02% to $82.0 million in 2023, then plummeted by 65.38% to $28.4 million in 2024, then fell by 20.13% to $22.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $22.7 million (Q4 2025), $25.8 million (Q3 2025), and $21.4 million (Q2 2025) per Business Quant data.